Last reviewed · How we verify
Atrophic vulva
Approved treatments
- Micronor · Johnson & Johnson
ORIAHNN combines elagolix, which suppresses LH and FSH to reduce ovarian sex hormones, with estradiol and norethindrone acetate to mitigate side effects. - Estrace · Pfizer
Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen. - Synestrol · Johnson & Johnson
- Ortho-Novum 10/11-21 · Merck & Co.
- Estring · Pfizer Inc.
Prevents pregnancy primarily by suppressing ovulation. - Slynd · Exeltis Usa Inc
Slynd works by binding to the mineralocorticoid receptor, a protein that plays a role in hormone regulation. - Osphena · Duchesnay
Osphena works by binding to estrogen receptors, specifically targeting estrogen receptor beta, to provide relief from symptoms of atrophic vulva and dyspareunia.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Atrophic vulva patent landscape — cliff calendar, originator estates, attackable patents
- Atrophic vulva treatment landscape brief
- Atrophic vulva treatment updates RSS
Frequently asked questions about Atrophic vulva
What drugs treat Atrophic vulva?
Tracked treatments include Micronor, Estrace, Synestrol, Ortho-Novum 10/11-21, Estring, Slynd, Osphena.
What is the treatment for Atrophic vulva?
Standard treatment for Atrophic vulva includes Micronor, Estrace, Synestrol, Ortho-Novum 10/11-21, Estring. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Atrophic vulva patent cliff · Atrophic vulva CI report
- Treatment: Micronor · Johnson & Johnson
- Treatment: Estrace · Pfizer
- Treatment: Synestrol · Johnson & Johnson
- Treatment: Ortho-Novum 10/11-21 · Merck & Co.
- Treatment: Estring · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing